October 2017

17 October 2017

Walk in interview for M.Pharm, B.Pharm, D.Pharm in Production & Packing at Glenmark Pharmaceuticals

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000 people in over 80 countries. It has twelve manufacturing facilities in four countries and has five R&D centres.

Post : JR.OFFICER/ OFFICER / SR. OFFICER

17 October 2017

DIPAS invites applications for Research Associate and Junior Research Fellows

Defence Institute of Physiology and Allied Sciences (DIPAS) invites applications for Research Associate and Junior Research Fellows Defence Institute of Physiology and Allied Sciences (DIPAS) provides an excellent opportunity for young and motivated researchers to pursue a career in basic and applied Life Sciences research. DIPAS endeavors in optimizing human performance under extreme operational environments using physiological, biochemical, nutritional and ergonomic approach. The labs are equipped with state-of-art facilities to conduct human studies, animal and in-vitro experimentation with an interdisciplinary approach. Applications are invited from young and motivated candidates to work in ongoing and future research projects of DIPAS for the following posts:

Read more about New gene expression signature assay can enhance lymphoma management

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype. In a report in the Journal of Molecular Diagnostics, researchers describe their development of a reliable, accessible, rapid, and cost-effective new gene expression signature assay that can enhance lymphoma management by helping to match tumors with the appropriate targeted therapy.

Read more about CRO Quality Benchmarking for Phase IV Service Providers : Research and Markets

ISR's CRO Quality Benchmarking - Phase IV Service Providers (9th Edition) report provides pharmaceutical sponsors and service providers a Consumer Reports-style analysis of CRO quality. Respondents supplied performance ratings based on their experiences with 24 Phase IV CROs, making this report the most comprehensive assessment of CRO service quality in the industry.

Read more about Takeda's Brigatinib found effective in Non-Small Cell Lung Cancer

Takeda Pharmaceutical Company Limited announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial evaluating ALUNBRIGTM (brigatinib) in patients with locally advanced or metastatic anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who have progressed on crizotinib will be presented in an oral session at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) on Monday, October 16, 4:30 p.m.- 4:40 p.m. JST. The presentation will share updated safety and efficacy data from the trial as of February 21, 2017, which continue to support previously reported clinical results.

Read more about Savolitinib exert positive clinical results for EGFR Mutation-positive Lung Cancer

AstraZeneca and its partner Chi-Med presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity. The data were shared in two oral presentations at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, 15-18 October 2017.

16 October 2017

Career for M.Pharm as Junior Research Fellow at R. C. Patel Institute of Pharmaceutical Education & Research

R. C. Patel Institute of Pharmaceutical Education & Research, Formerly known as R.C. Patel College of Pharmacy established in June 1992 with the aim to enhance the quality education in the field of Pharmacy and empower the quality pharmacist so that they serve the society to develop lifesaving drugs. Right from its establishment the institute has maintained the quality with assurance in terms of Accreditation from National Board of Accreditation, New Delhi (NBA) twice on 2005 and 2009 for the B. Pharm course. Institute also accredited by NAAC, Bangalore for the period of 5 years. In addition to this institute has approved by, All India Council for Technical Education, New Delhi.

Post : Junior Research Fellow

16 October 2017

Walk in Interviews for M.Pharma, M.Sc Freshers at Annora Pharma Private Limited | Formulations/OSD

Annora Pharma Private Limited is a Private incorporated on 26 November 2015. It is classified as Non-govt company and is registered at Registrar of Companies, Hyderabad. Its authorized share capital is Rs. 50,000,000 and its paid up capital is Rs. 10,000,000.It is inolved in Manufacture of basic chemicals

16 October 2017

Job for B.Pharm/M.Pharm as Committee Coordinator at Global Hospitals

Global Hospitals Group is one of the fast growing chains of multi super specialty tertiary & quaternary care Hospitals in India offering healthcare services of international standards. Conferred with many prestigious Health Care excellence awards and recognized as the most promising Healthcare chain in India, Global Hospitals Group, with over 2000 beds, has world class hospitals strategically located in the metro cities of Chennai, Bangalore, Hyderabad & Mumbai.

Post : Ethics Committee Coordinator

16 October 2017

Walk in interview Fresher in Manufacturing, R&D & QC at Hetero Drugs

Hetero Drugs established in the year 1993, with the motto to be the best in the API manufacturing, Hetero today embodies the vision of a top notch player in developing and commercialising products catering to a variety of therapeutic categories, integrating into a leading finished dosage manufacturer.

True to the Statement, "Where the Future Started Yesterday", with a foresight on the current trends in the Pharmaceutical Market, Hetero has grown from strength to strength, combining its Research Strengths, Manufacturing Capabilities ,Human Resources and well established quality management system.

Post : Manufacturing, R&D & QC depts